Trisomy 21 screening is one of the first critical steps in prenatal care. Available from 11 weeks of gestation, this non-invasive test helps identify whether your baby may be at higher risk for Down syndrome before birth.
Screening for trisomy 21 combines biochemical markers (maternal serum proteins) with specialized ultrasound imaging (nuchal translucency measurement). Unlike diagnostic tests such as amniocentesis, screening provides a risk assessment, not a definitive diagnosis. This distinction is important for planning your pregnancy pathway and understanding your options.
In Turkey, obstetricians and maternal-fetal medicine specialists offer three main screening approaches: combined first-trimester screening (weeks 11–14),quad screening in the second trimester (weeks 15–22),and non-invasive prenatal testing (NIPT) using cell-free fetal DNA. Each has different detection rates, timing requirements, and cost considerations. Clinics partnered with Turquie Santé provide counseling to help you choose the approach that suits your clinical situation and preferences.
This page explains how each test works, what results mean, realistic timelines for receiving them, and the next steps if your screening indicates elevated risk.





































































